{"result": "(\"entity\"<|>MIGUEL A. RUBIO HERRERA<|>PERSON<|>Miguel A. Rubio Herrera is a licensed physician and specialist in Endocrinology and Nutrition, currently serving as the Head of the Clinical Nutrition and Dietetics Section at Hospital Clínico San Carlos in Madrid.)\n##\n(\"entity\"<|>HOSPITAL CLÍNICO SAN CARLOS<|>ORGANIZATION<|>Hospital Clínico San Carlos is a medical institution in Madrid where Miguel A. Rubio Herrera works, focusing on clinical nutrition, obesity, and vascular risk.)\n##\n(\"entity\"<|>UNIVERSIDAD AUTÓNOMA DE BARCELONA<|>ORGANIZATION<|>Universidad Autónoma de Barcelona is the university where Miguel A. Rubio Herrera obtained his medical degree in 1982.)\n##\n(\"entity\"<|>UNIVERSIDAD COMPLUTENSE DE MADRID<|>ORGANIZATION<|>Universidad Complutense de Madrid is the university where Miguel A. Rubio Herrera completed his doctorate in 1989 and is currently a professor associated with.)\n##\n(\"entity\"<|>SEEN<|>ORGANIZATION<|>SEEN is the Spanish Society of Endocrinology and Nutrition, where Miguel A. Rubio Herrera participates in various working groups related to obesity and nutrition.)\n##\n(\"entity\"<|>SEEDO<|>ORGANIZATION<|>SEEDO is the Spanish Society for the Study of Obesity, involved in consensus development regarding obesity treatment, in which Miguel A. Rubio Herrera participates.)\n##\n(\"entity\"<|>NAOS<|>EVENT<|>NAOS is a strategy developed in Spain aimed at addressing obesity and promoting healthy lifestyles, with contributions from Miguel A. Rubio Herrera.)\n##\n(\"entity\"<|>DRECE<|>EVENT<|>DRECE is a study focused on the epidemiology of cardiovascular risk in Spain, in which Miguel A. Rubio Herrera has been involved.)\n##\n(\"relationship\"<|>MIGUEL A. RUBIO HERRERA<|>HOSPITAL CLÍNICO SAN CARLOS<|>Miguel A. Rubio Herrera is the Head of the Clinical Nutrition and Dietetics Section at Hospital Clínico San Carlos<|>9)\n##\n(\"relationship\"<|>MIGUEL A. RUBIO HERRERA<|>UNIVERSIDAD AUTÓNOMA DE BARCELONA<|>Miguel A. Rubio Herrera graduated from Universidad Autónoma de Barcelona in 1982<|>5)\n##\n(\"relationship\"<|>MIGUEL A. RUBIO HERRERA<|>UNIVERSIDAD COMPLUTENSE DE MADRID<|>Miguel A. Rubio Herrera completed his doctorate at Universidad Complutense de Madrid in 1989 and is currently a professor there<|>7)\n##\n(\"relationship\"<|>MIGUEL A. RUBIO HERRERA<|>SEEN<|>Miguel A. Rubio Herrera participates in working groups of the SEEN related to obesity and nutrition<|>6)\n##\n(\"relationship\"<|>MIGUEL A. RUBIO HERRERA<|>SEEDO<|>Miguel A. Rubio Herrera is involved in the development of consensus on obesity treatment with SEEDO<|>6)\n##\n(\"relationship\"<|>MIGUEL A. RUBIO HERRERA<|>NAOS<|>Miguel A. Rubio Herrera has contributed to the development of the NAOS strategy to combat obesity<|>5)\n##\n(\"relationship\"<|>MIGUEL A. RUBIO HERRERA<|>DRECE<|>Miguel A. Rubio Herrera is involved in the DRECE study focusing on cardiovascular risk epidemiology in Spain<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: del valor basal apoya el diagnóstico.\n\nAntes de la aparición de los fármacos antagonistas de H2 y fundamentalmente de los inhibidores de la bomba de protones, las complicaciones del gastrinoma eran la principal causa de mortalidad y morbilidad del síndrome MEN1; tras la introducción de estos fármacos se han reducido drásticamente.\n\nEl tratamiento del gastrinoma es controvertido. Para algunos grupos, el tratamiento solo deber ser médico, con inhibidores de la bomba de protones; sin embargo, otros autores consideran que el tratamiento debe ser quirúrgico, con el fin de disminuir el riesgo de desarrollar metástasis hepáticas, que suelen ocurrir en el 20-30% de los pacientes y determinan la supervivencia.\n\nLa técnica más frecuentemente utilizada es la desarrollada por Thompson: duodenotomía más pancreatectomía distal (80% del páncreas) para extirpar los tumores no funcionantes que habitualmente también están presentes; además, se realizará la enucleación de los tumores de la cabeza pancreática y una cuidadosa limpieza ganglionar porque el 40-70% de los pacientes tienen metástasis ganglionares, lo que dificulta aún más la curación. Esta técnica tiene una baja tasa de curación (16%) y una alta tasa de recurrencia, por lo que desde hace unos años algunos autores recomiendan realizar una pancreatoduodenectomía, o duodenectomía. Con estas técnicas hasta el 77% de los pacientes tenían una gastrina normal, pero se desconoce durante cuánto tiempo se mantiene la curación y si mejora la supervivencia.\n\nDebido a la morbilidad asociada a la cirugía y las pocas expectativas de curación, la recomendación de la Guía Clínica de 2012 y aceptada por la mayoría de los grupos es intervenir pacientes con síndrome de Zollinger-Ellison y tumores pancreáticos de más de 2,5 cm, porque diferentes estudios encontraron que los pacientes con tumores inferiores a 2,5 cm tenían una supervivencia del 100% a los 15 años y solo el 14-25% de los gastrinomas tenían un comportamiento agresivo, y de estos, el 100% tenían tumores pancreáticos superiores a 3 cm.\n\n### Referencias:\n- Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n- Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:1-22.\n- Valdés Gallego N. Manual de Endocrinología y Nutrición (Internet). Capítulo 3. Neoplasia Endocrina Múltiple. Madrid: Sociedad Española de Endocrinología y Nutrición; 2015. Disponible en: https://manual.seen.es\n---\nThe image provided appears to be entirely blank or white. There is no visible content, text, diagrams, or any other discernible information on this page. Therefore, I cannot provide any markdown translation or description of content, as there is nothing to transcribe or describe.\n---\nMÓDULO 8\n\nObesidad, lípidos\ny trastornos electrolíticos\nObesidad\n\nAUTOR\n\nMiguel A. Rubio Herrera\n\n▶ Licenciado en Medicina y Cirugía por la Universidad Autónoma de Barcelona (1982) y doctor por la Universidad Complutense de Madrid (1989). Especialista en Endocrinología y Nutrición en el Hospital Clínico San Carlos de Madrid (1987). Actualmente, es Jefe de Sección de Nutrición Clínica y Dietética y de Obesidad y Riesgo Vascular del Servicio de Endocrinología y Nutrición del Hospital Clínico San Carlos. Así mismo, es profesor asociado de Medicina y titular acreditado por la ANECA por la Universidad Complutense de Madrid.\n\n▶ Las áreas de interés (asistenciales, docente e investigadoras) se han centrado en el ámbito de la obesidad, dislipidemia, diabetes y nutrición: epidemiología del riesgo cardiovascular en España (estudio DRECE), grupo de trabajo de Lípidos de la SEEN, participación en consensos de obesidad de la SEEDO, consensos de cirugía bariátrica y en el desarrollo de la estrategia NAOS, y publicación del libro Manual de Obesidad mórbida, entre otros. Participación en ensayos clínicos de obesidad. Grupo de trabajo de Obesidad de la SEEN, trabajos previos en el grupo de optimización de diabetes de la SED, epidemiología en DM2 y riesgo cardiovascular. Ensayos clínicos en diabetes, grupo de trabajo de Nutrición de la SEEN. Más de 100 publicaciones indexadas (índice H: 24), más de 300 comunicaciones y\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}